LODE Comstock Inc.
Industrial Organic Chemicals · NYSE · SEC CIK 1120970 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-52.2%
TTM net income YoY7.1%
TTM EPS YoY—
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—
Margins
Gross margin-151.8%
Operating margin-3,535.2%
Net margin-3,680.5%
FCF margin—
EBITDA margin-3,173.9%
Returns
ROE-38.2%
ROA-27.2%
ROIC (approx.)-40.2%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets22.9%
Debt / equity0.00x
Current ratio3.31x
Interest coverage-67.29x
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.55M | $3.02M |
| Cost of revenue | $2.63M | $451,938 |
| Gross profit | -$1.07M | $2.56M |
| R&D expense | $12.32M | $19.10M |
| SG&A expense | $20.67M | $12.70M |
| Operating income | -$38.15M | -$39.67M |
| Interest expense | $1.93M | $2.97M |
| Pretax income | $43.08M | $53.32M |
| Income tax | $0 | $0 |
| Net income | -$43.08M | -$53.32M |
| EBITDA | -$34.31M | -$37.42M |
| EPS (basic) | -1.17 | -3.21 |
| EPS (diluted) | -1.17 | -3.21 |
| Weighted avg. shares (diluted) | 36.71M | 16.61M |
| Balance sheet | ||
| Cash & equivalents | $16.95M | $954,271 |
| Short-term investments | — | $0 |
| Receivables | $1.29M | $2.42M |
| Current assets | $20.66M | $12.56M |
| PP&E, net | $29.89M | $8.61M |
| Goodwill | $1.51M | $0 |
| Intangibles | $26.45M | $5.86M |
| Total assets | $169.60M | $91.31M |
| Current liabilities | $10.02M | $8.11M |
| Short-term debt | $0 | $97,593 |
| Long-term debt | $0 | $8.39M |
| Total debt | $0 | $8.49M |
| Total liabilities | $58.70M | $31.54M |
| Shareholders' equity | $107.58M | $59.77M |
| Net debt | -$16.95M | $7.53M |
| Shares outstanding | 51.85M | 23.51M |
| Cash flow statement | ||
| Operating cash flow | -$24.39M | -$13.94M |
| Investing cash flow | -$21.98M | -$6.48M |
| Financing cash flow | $62.36M | $17.59M |
| Depreciation & amortization | $3.84M | $2.24M |
| Stock-based compensation | $0 | $41,799 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.